Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Irbesartan Tablets in Healthy Subjects
NCT05297929Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of irbesartan in hypertension (HTN) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration up to 1 year, Area Under the Curve from time 0 to infinity up to 1 year and 3 more. Status: unknown.
02
Drugs
irbesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05297929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297929.